Zucara Therapeutics is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in patients with diabetes. This pre-clinical technology is directed at regulating a hormone in the pancreas called somatostatin which in Type 1 diabetes is not properly controlled. It has demonstrated potential to specifically blocksomatostatin type 2 receptors in the pancreas thereby preventing hypoglycemia and restoring natural glucose levels in the blood. Zucara’s method offers a clear advantage to patients as a preventative measure whereas current drug therapies can only rescue a patient already experiencing potentially dangerous low blood sugar.

Biotechnology

Health Care

Zucara Therapeutics Inc.

Org chart

Teams

Similar companies